Shanghai Pharmaceuticals Announces Equity Adjustment; No Change in Controlling Shareholder

Reuters10-14

Shanghai Pharmaceuticals Announces Equity Adjustment; No Change in Controlling Shareholder

Shanghai Pharmaceuticals Holding Co. Ltd. has announced the completion of an equity adjustment involving its controlling shareholder. The reorganization included the transfer of Shanghai Shangshi (Group) Co., Ltd.'s 100% equity interest in Shanghai Tandong Enterprise Consulting Services Co., Ltd. to SIIC International Investment Company Limited, as well as the disposal of a 40% equity interest in Shanghai Pharmaceutical (Group) Co., Ltd. With these transactions, SIIC International increased its shareholding to 301,418,000 H shares, and Shanghai Shangshi's indirect control of the company rose from 25.303% to 38.487%. The company stated that the equity adjustment will not result in any change to its controlling shareholder or de facto controller.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Pharmaceuticals Holding Co. Ltd. published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2575299075?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 18:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575299075","market":"fut","top_or_hot":-1,"title":"Shanghai Pharmaceuticals Announces Equity Adjustment; No Change in Controlling Shareholder","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Shanghai Pharmaceuticals Announces Equity Adjustment; No Change in Controlling Shareholder\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Shanghai Pharmaceuticals Holding Co. Ltd. has announced the completion of an equity adjustment involving its controlling shareholder. The reorganization included the transfer of Shanghai Shangshi (Group) Co., Ltd.'s 100% equity interest in Shanghai Tandong Enterprise Consulting Services Co., Ltd. to SIIC International Investment Company Limited, as well as the disposal of a 40% equity interest in Shanghai Pharmaceutical (Group) Co., Ltd. With these transactions, SIIC International increased its shareholding to 301,418,000 H shares, and Shanghai Shangshi's indirect control of the company rose from 25.303% to 38.487%. The company stated that the equity adjustment will not result in any change to its controlling shareholder or de facto controller.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Pharmaceuticals Holding Co. Ltd. published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharmaceuticals Announces Equity Adjustment; No Change in Controlling Shareholder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharmaceuticals Announces Equity Adjustment; No Change in Controlling Shareholder\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-14 18:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Shanghai Pharmaceuticals Announces Equity Adjustment; No Change in Controlling Shareholder\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Shanghai Pharmaceuticals Holding Co. Ltd. has announced the completion of an equity adjustment involving its controlling shareholder. The reorganization included the transfer of Shanghai Shangshi (Group) Co., Ltd.'s 100% equity interest in Shanghai Tandong Enterprise Consulting Services Co., Ltd. to SIIC International Investment Company Limited, as well as the disposal of a 40% equity interest in Shanghai Pharmaceutical (Group) Co., Ltd. With these transactions, SIIC International increased its shareholding to 301,418,000 H shares, and Shanghai Shangshi's indirect control of the company rose from 25.303% to 38.487%. The company stated that the equity adjustment will not result in any change to its controlling shareholder or de facto controller.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Pharmaceuticals Holding Co. Ltd. published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0183","symbol_name":"MSCI概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDLbzQsQv:1","article_id":"2575299075","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575299075","pubTimestamp":1760439060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Shanghai Pharmaceuticals Holding Co. Ltd. has announced the completion of an equity adjustment involving its controlling shareholder. The reorganization included the transfer of Shanghai Shangshi  Co., Ltd.'s 100% equity interest in Shanghai Tandong Enterprise Consulting Services Co., Ltd. to SIIC International Investment Company Limited, as well as the disposal of a 40% equity interest in Shanghai Pharmaceutical  Co., Ltd. With these transactions, SIIC International increased its shareholding to 301,418,000 H shares, and Shanghai Shangshi's indirect control of the company rose from 25.303% to 38.487%. The company stated that the equity adjustment will not result in any change to its controlling shareholder or de facto controller.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0183":"MSCI概念","BK0209":"零售","BK0188":"融资融券","BK0175":"白马股","BK0012":"证金概念","BK0196":"行业龙头","BK0187":"一线龙头","BK0097":"医药电商","BK0184":"上海国资改革","BK0099":"上海本地重组","BK0028":"国家队","BK0020":"浦东新区"},"translate_title":"上海医药公告股权调整；控股股东无变动","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":0.9},"content_text":"Shanghai Pharmaceuticals Announces Equity Adjustment; No Change in Controlling Shareholder\n    \n\n        Shanghai Pharmaceuticals Holding Co. Ltd. has announced the completion of an equity adjustment involving its controlling shareholder. The reorganization included the transfer of Shanghai Shangshi (Group) Co., Ltd.'s 100% equity interest in Shanghai Tandong Enterprise Consulting Services Co., Ltd. to SIIC International Investment Company Limited, as well as the disposal of a 40% equity interest in Shanghai Pharmaceutical (Group) Co., Ltd. With these transactions, SIIC International increased its shareholding to 301,418,000 H shares, and Shanghai Shangshi's indirect control of the company rose from 25.303% to 38.487%. The company stated that the equity adjustment will not result in any change to its controlling shareholder or de facto controller.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Pharmaceuticals Holding Co. Ltd. published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2575299075","isCrawlerRequest":true}